Literature DB >> 15812223

Good manufacturing practice production of adenoviral vectors for clinical trials.

Monika Lusky1.   

Abstract

The increasing importance of recombinant adenoviral vectors for gene therapy, cancer therapy, and the development of prophylactic and therapeutic vaccines has led to worldwide efforts toward scalable process development suitable for commercial manufacturing of replication-deficient adenoviral vectors. This review focuses on the manufacturing of adenovirus for clinical trials in the context of good manufacturing practice conditions and regulations.

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 15812223     DOI： 10.1089/hum.2005.16.281

Source DB:  PubMed          Journal:  Hum Gene Ther        ISSN： 1043-0342            Impact factor:   5.695


  18 in total

Review 1.  Cancer immunotherapy: a paradigm shift for prostate cancer treatment.

Authors:  Dev Karan; Jeffrey M Holzbeierlein; Peter Van Veldhuizen; J Brantley Thrasher
Journal:  Nat Rev Urol       Date:  2012-05-29       Impact factor: 14.432

2.  Phase II clinical trial of intratumoral application of TG1042 (adenovirus-interferon-gamma) in patients with advanced cutaneous T-cell lymphomas and multilesional cutaneous B-cell lymphomas.

Authors:  Reinhard Dummer; Stefan Eichmüller; Sylke Gellrich; Chalid Assaf; Brigitte Dreno; Meinhard Schiller; Olivier Dereure; Marion Baudard; Martine Bagot; Amir Khammari; Pascal Bleuzen; Vincent Bataille; Anna Derbij; Nicole Wiedemann; Tim Waterboer; Monika Lusky; Bruce Acres; Mirjana Urosevic-Maiwald
Journal:  Mol Ther       Date:  2010-04-06       Impact factor: 11.454

3.  Cas9-nickase-mediated genome editing corrects hereditary tyrosinemia in rats.

Authors:  Yanjiao Shao; Liren Wang; Nana Guo; Shengfei Wang; Lei Yang; Yajing Li; Mingsong Wang; Shuming Yin; Honghui Han; Li Zeng; Ludi Zhang; Lijian Hui; Qiurong Ding; Jiqin Zhang; Hongquan Geng; Mingyao Liu; Dali Li
Journal:  J Biol Chem       Date:  2018-03-05       Impact factor: 5.157

4.  The Effect of CXCR4 Overexpression on Mesenchymal Stem Cell Transplantation in Ischemic Stroke.

Authors:  Oh Young Bang; Kyung Sil Jin; Mi Na Hwang; Ho Young Kang; Byoung Joon Kim; Sang Jin Lee; Sangmee Kang; Yu Kyeong Hwang; Jong Seong Ahn; Ki Woong Sung
Journal:  Cell Med       Date:  2012-05-15

Review 5.  Production of adenovirus vectors and their use as a delivery system for influenza vaccines.

Authors:  Sai V Vemula; Suresh K Mittal
Journal:  Expert Opin Biol Ther       Date:  2010-10       Impact factor: 4.388

Review 6.  Innate immunity to adenovirus.

Authors:  Rodinde Hendrickx; Nicole Stichling; Jorien Koelen; Lukasz Kuryk; Agnieszka Lipiec; Urs F Greber
Journal:  Hum Gene Ther       Date:  2014-04-08       Impact factor: 5.695

7.  Adenoviral producer cells.

Authors:  Imre Kovesdi; Susan J Hedley
Journal:  Viruses       Date:  2010-08-16       Impact factor: 5.818

8.  Transduction Enhancers Enable Efficient Human Adenovirus Type 5-Mediated Gene Transfer into Human Multipotent Mesenchymal Stromal Cells.

Authors:  Robin Nilson; Olivia Lübbers; Linus Weiß; Karmveer Singh; Karin Scharffetter-Kochanek; Markus Rojewski; Hubert Schrezenmeier; Philip Helge Zeplin; Wolfgang Funk; Lea Krutzke; Stefan Kochanek; Astrid Kritzinger
Journal:  Viruses       Date:  2021-06-12       Impact factor: 5.048

Review 9.  Advances and future challenges in recombinant adenoviral vectored H5N1 influenza vaccines.

Authors:  Jianfeng Zhang
Journal:  Viruses       Date:  2012-11-01       Impact factor: 5.048

10.  Mesenchymal stem cells expressing TRAIL lead to tumour growth inhibition in an experimental lung cancer model.

Authors:  Andrea Mohr; Mark Lyons; Laura Deedigan; Tina Harte; Georgina Shaw; Linda Howard; Frank Barry; Tim O'Brien; Ralf Zwacka
Journal:  J Cell Mol Med       Date:  2008-03-28       Impact factor: 5.310
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.